RT Journal Article
SR Electronic
T1 Molecular markers for early stratification of disease severity and progression in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.06.22270355
DO 10.1101/2022.02.06.22270355
A1 Anusha,
A1 Sebastian, Savitha Anne
A1 Raksha, N.
A1 Raksha, K.
A1 Krishnamurthy, H.
A1 Krishna, Bhuvana
A1 D’Souza, George
A1 Idiculla, Jyothi
A1 Vyas, Neha
YR 2022
UL http://medrxiv.org/content/early/2022/02/07/2022.02.06.22270355.abstract
AB COVID-19 infections have imposed immense pressure on the healthcare system of most countries. While the initial studies have identified better therapeutic and diagnostic approaches, the disease severity is still assessed by close monitoring of symptoms by healthcare professionals due to the lack of biomarkers for disease stratification. In this study, we have probed the immune and molecular profiles of COVID-19 patients at 48-hour intervals after hospitalization to identify early markers, if any, of disease progression and severity. Our study reveals that the molecular profiles of patients likely to enter the host-immune response mediated moderate or severe disease progression are distinct even in the early phase of infection when severe symptoms are not yet apparent. Our data from 37 patients suggest that at hospitalization, IL6 (>300pg/ml) and IL8 levels (>200pg/ml) identify cytokine-dependent disease progression. Monitoring their levels will facilitate timely intervention using available immunomodulators or precision medicines in those likely to progress due to cytokine storm and help improve outcomes. Additionally, it will also help identify cytokine-independent progressive patients, not likely to benefit from immuno-modulators or precision drugs.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.notapplicable.com Funding StatementStandard Chartered to the COVID19 Response at Bangalore Life Science Cluster at Bengaluru and NV lab is supported by DSTCRG/2019/005347 and DBTBRB/BT/PR26240/BRB/10/1626/2017 grant and Anusha is supported by DSTCRG/2019/005347 grant to NV.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Commitee of St Johns Medical College and Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://www.notapplicable.com